Aug. 7 at 4:49 PM
$MCRB
The combined market capitalization of a merged Seres Therapeutics and Vedanta Biosciences entity is estimated to be in the range of
$400 million to
$800 million, with a base case of ~
$527 million (Seres’
$127M + Vedanta’s estimated
$400M) and a synergy-adjusted range of
$600–
$800 million assuming a 20–50% premium. This range accounts for Vedanta’s estimated valuation (based on
$366M in funding and Phase 3 readiness), Seres’ current market cap, and potential market reactions. The exact market cap would depend on merger structure, investor sentiment, and clinical milestones. For a more precise estimate, detailed merger terms and Vedanta’s financials would be needed, which are currently unavailable due to its private status.
